Literature DB >> 35768646

Deubiquitinase OTUD6A promotes breast cancer progression by increasing TopBP1 stability and rendering tumor cells resistant to DNA-damaging therapy.

Yan Zhao1,2, Xinping Huang1,2, Dan Zhu1,2, Min Wei1,2, Jiechen Luo1,2, Shuyu Yu1,2, Yonglu Tian1,3, Xiaofeng Zheng4,5.   

Abstract

The DNA damage response (DDR) is critical for maintaining cellular homeostasis and genome integrity. Mounting evidence has shown that posttranslational protein modifications play vital roles in the DDR. In this study, we showed that deubiquitinase OTUD6A is involved in the DDR and is important for maintaining genomic stability. Mechanistically, in response to DNA damage, the abundance of OTUD6A was increased; meanwhile, PP2A interacted with OTUD6A and dephosphorylated OTUD6A at sites S70/71/74, which promoted nuclear localization of OTUD6A. Subsequently, OTUD6A was recruited to the damage site, where it interacted with TopBP1 and blocked the interaction between TopBP1 and its ubiquitin E3 ligase UBR5, decreasing K48-linked polyubiquitination and increasing the stability of TopBP1. OTUD6A depletion impaired CHK1 S345 phosphorylation and blocked cell cycle progression under DNA replication stress. Consistently, knockout of OTUD6A rendered mice hypersensitive to irradiation, shortened survival, and inhibited tumor growth by regulating TopBP1 in xenografted nude mice. Moreover, OTUD6A is expressed at high levels in breast cancer, and OTUD6A overexpression promotes cell proliferation, migration and invasion, indicating that dysregulation of OTUD6A expression contributes to genomic instability and is associated with tumor development. In summary, this study demonstrates that OTUD6A plays a critical role in promoting tumor cell resistance to chemoradiotherapy by deubiquitinating and stabilizing TopBP1.
© 2022. The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare.

Entities:  

Year:  2022        PMID: 35768646     DOI: 10.1038/s41418-022-01036-6

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  47 in total

1.  RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins.

Authors:  Carsten Doil; Niels Mailand; Simon Bekker-Jensen; Patrice Menard; Dorthe Helena Larsen; Rainer Pepperkok; Jan Ellenberg; Stephanie Panier; Daniel Durocher; Jiri Bartek; Jiri Lukas; Claudia Lukas
Journal:  Cell       Date:  2009-02-06       Impact factor: 41.582

Review 2.  DNA damage, aging, and cancer.

Authors:  Jan H J Hoeijmakers
Journal:  N Engl J Med       Date:  2009-10-08       Impact factor: 91.245

Review 3.  The DNA-damage response in human biology and disease.

Authors:  Stephen P Jackson; Jiri Bartek
Journal:  Nature       Date:  2009-10-22       Impact factor: 49.962

4.  RNF168 promotes noncanonical K27 ubiquitination to signal DNA damage.

Authors:  Marco Gatti; Sabrina Pinato; Alessio Maiolica; Francesca Rocchio; Maria Giulia Prato; Ruedi Aebersold; Lorenza Penengo
Journal:  Cell Rep       Date:  2015-01-08       Impact factor: 9.423

Review 5.  Preserving genome integrity and function: the DNA damage response and histone modifications.

Authors:  Jae Jin Kim; Seo Yun Lee; Kyle M Miller
Journal:  Crit Rev Biochem Mol Biol       Date:  2019-06-04       Impact factor: 8.250

Review 6.  SUMO-mediated regulation of DNA damage repair and responses.

Authors:  Prabha Sarangi; Xiaolan Zhao
Journal:  Trends Biochem Sci       Date:  2015-03-13       Impact factor: 13.807

Review 7.  State-of-the-art strategies for targeting the DNA damage response in cancer.

Authors:  Patrick G Pilié; Chad Tang; Gordon B Mills; Timothy A Yap
Journal:  Nat Rev Clin Oncol       Date:  2019-02       Impact factor: 66.675

8.  RNF111-dependent neddylation activates DNA damage-induced ubiquitination.

Authors:  Teng Ma; Yibin Chen; Feng Zhang; Chao-Yie Yang; Shaomeng Wang; Xiaochun Yu
Journal:  Mol Cell       Date:  2013-02-07       Impact factor: 17.970

Review 9.  DNA repair pathways as targets for cancer therapy.

Authors:  Thomas Helleday; Eva Petermann; Cecilia Lundin; Ben Hodgson; Ricky A Sharma
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

10.  Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer.

Authors:  Jian Cao; Qin Yan
Journal:  Front Oncol       Date:  2012-03-12       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.